Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $66.66 USD
Change Today 0.00 / 0.00%
Volume 0.0
CHGCY On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 8:10 PM 06/22/15 All times are local (Market data is delayed by at least 15 minutes).

chugai pharmaceutic-unsp adr (CHGCY) Key Developments

Chugai Pharmaceutical Co., Ltd. Announces Integration and Reorganization of Overseas Subsidiaries

Chugai Pharmaceutical Co. Ltd. announced that it will integrate and reorganize its subsidiaries in Europe, China and Taiwan in order to further accelerate its overseas business activities. This integration and reorganization have two major purposes. On April 1, 2015, Chugai established the Translational Clinical Research (TCR) Division in order to rapidly acquire early Proof-of-Concept (PoC) for drugs under development that had been discovered and created in-house. The first purpose is to straighten the internal structure as the TCR Division will be in full operation. In addition, until now, the company had separated its activities such as clinical development, import, and sales into respective subsidiary companies depending on the function in each country. By integrating these functions into one company, Chugai will streamline the operations from development to sales and marketing. This will enhance its specialty of each function as well as the competence to collaborate and work together to increase customer satisfaction. The second purpose is to develop Chugai's unique business to provide high value-added services by further strengthening the foundation of its business through this integration and reorganization. Details of this integration and reorganization in Europe, China and Taiwan are: [Europe] he business function of Chugai Pharma Europe Ltd. will be transferred to Chugai Pharma Marketing Ltd. and the two companies will be integrated as of July 1, 2015. hugai Pharma Europe Ltd. will initiate the liquidation proceedings in due course after completion of transferring procedure. verview of the Post-reorganized company. Company name: Chugai Pharma Marketing Ltd. Location: Mulliner House, Flanders Road, Turnham Green, London W4 1NN, U.K. Capital: 8,677,808 GBP (100% Owned by Chugai). Activities: Clinical development, regulatory affairs, medical affairs, import, sales and marketing of pharmaceutical products in Europe. Representative: John Halls (Managing Director of current Chugai Pharma Marketing Ltd.). Number of Employees: 49 [China] he business function of Chugai Pharma (Shanghai) Consulting Co. Ltd. will be transferred to Chugai Pharma China Co. Ltd. hugai Pharma (Shanghai) Consulting Co. Ltd. will initiate the liquidation proceedings in due course after completion of transferring procedure. verview of the Post-reorganized Company. Company name: Chugai Pharma (China) Co. Ltd. Location: Building G31, No. 801 Jiankang Dadao, Medical City Taizhou, Jiangsu 225300 . Capital: 30 million USD (100% Owned by Chugai). Activities: Import and sales of the pharmaceutical products in China. Representative: Takashi Sakabe (Representative of current Chugai Pharma China Co. Ltd.). Number of Employees: 54 [Taiwan] hugai Pharma R&D Taiwan Ltd., a subsidiary which conducts clinical development and related business activities of products contracted by Chugai or Chugai Pharma Taiwan Ltd., will integrate with Chugai Pharma Taiwan Ltd. hugai Pharma R&D Taiwan Ltd. will initiate the liquidation proceedings in due course after completion of transferring procedure. verview of the Post-reorganized Company. Company name: Chugai Pharma Taiwan Ltd. Location: 3Fl., No. 73, ZhouZi Street, Neihu District, Taipei 11493 Taiwan. Capital: 33,376,000 TWD (100% Owned by Chugai). Activities: Clinical development, regulatory affairs, import, sales and marketing of the pharmaceutical products in Taiwan. Representative: Tatsuji Shimada (Representative of current Chugai Pharma Taiwan Ltd. and Department manager of Overseas Business Dept.). Number of Employees: 63 Under its business philosophy 'Innovation all for the patients,' Chugai is committed to creating new value through offering innovative medical products and services, thereby contributing to healthcare and human health around the world.

Chugai Pharmaceutical Co. Ltd. Presents at BIO International Convention 2015, Jun-16-2015 11:00 AM

Chugai Pharmaceutical Co. Ltd. Presents at BIO International Convention 2015, Jun-16-2015 11:00 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.

Chugai Pharmaceutical Co. Ltd., Board Meeting, Apr 22, 2015

Chugai Pharmaceutical Co. Ltd., Board Meeting, Apr 22, 2015. Agenda: To amend basic policies concerning internal controls.

Chugai Pharmaceutical Co. Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Consolidated Earnings Guidance for the Year Ending December 31, 2015

Chugai Pharmaceutical Co. Ltd. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported core and IFRS revenues of JPY 117,083 million compared to JPY 124,045 million a year ago. Operating profit was JPY 20,750 million compared to JPY 31,089 million a year ago. Profit before taxes was JPY 21,174 million compared to JPY 31,263 million a year ago. Net income was JPY 14,819 million compared to JPY 19,080 million a year ago. Net income attributable to the shareholders was JPY 14,582 million compared to JPY 18,776 million a year ago. Diluted net income per share was JPY 26.68 compared to JPY 34.41 a year ago. Core operating profit was JPY 27.54 per share. Core operating profit was JPY 21.5 billion against JPY 31.4 billion last year, a decrease of 31.5% year on year. Core net income was JPY 15.3 billion against JPY 19.3 billion last year, a decrease of 20.7% year on year, due to the improvements in other financial income (expense) and the reduction of the tax burden ratio due mainly to the changes in the taxation system. Cash flows from operating activities were JPY 33.3 billion compared to JPY 15.4 billion last year. Free cash flows were JPY 10.8 billion against negative free cash flows of JPY 3.6 billion last year. Purchase of property, plant and equipment was JPY 5.1 billion against JPY 5.6 billion last year. Purchase of intangible assets was JPY 2.1 billion against JPY 721 million last year. Ratio of net income to equity attributable to Chugai shareholders (ROE) was 2.5% against 3.3% last year. Ratio of profit before taxes to total assets (ROA) was 2.9% against 4.5% last year. Core return on net operating assets (core RONOA) was 4.5% against 5.8% last year. Core profit before taxes was JPY 21.9 billion compared to JPY 31.6 billion a year ago. Core net income attributable to the shareholders was JPY 15.1 billion against JPY 19.0 billion last year. Core earnings per diluted share were JPY 27.54 against JPY 34.82 last year. On consolidated basis, the company reaffirmed earnings guidance for the year ending December 31, 2015. The company expects revenues of JPY 486,500 million, core operating profit of JPY 85,000 million and core earnings per share of JPY 104.42. The company expecting 5.5% growth in sales compared to the previous year. The company forecasting JPY 0.7 billion sales for the remaining 9 months this year.

Chugai Pharmaceutical Co. Ltd., Q1 2015 Earnings Call, Apr 22, 2015

Chugai Pharmaceutical Co. Ltd., Q1 2015 Earnings Call, Apr 22, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CHGCY:US $66.66 USD 0.00

CHGCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CHGCY.
View Industry Companies
 

Industry Analysis

CHGCY

Industry Average

Valuation CHGCY Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHUGAI PHARMACEUTIC-UNSP ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.